Scientist aims to improve breast cancer treatments
Around 40 per cent of cancers are resistant to chemotherapy and some patients will see their breast cancer return.
Dr Weiguang Wang aims to improve the outcome for these patients by studying whether resistance can be prevented or reversed. He believes a molecule called NF-kB may be responsible for stopping chemotherapy from working. He will investigate whether treating breast cancer cells with disulfiram, a drug used in the treatment of alcoholism and which specifically targets NF-kB, will make cells more sensitive to chemotherapy.
The pilot grant is the first awarded to the University of Wolverhampton by Breast Cancer Campaign, one of the UK’s leading breast cancer research charities.
Dr Wang, from the University’s Research Institute in Healthcare Science, said: “I am delighted to be the first Wolverhampton-based scientist to be awarded a Breast Cancer Campaign grant. I hope this study will lead to the development of a new drug which will improve breast cancer chemotherapy in the clinic.”
Pamela Goldberg, Chief Executive, Breast Cancer Campaign, said: “Despite the availability of many effective treatments almost 12,500 women will still die from breast cancer each year. It is therefore vital that scientists look at ways to improve the effectiveness of current treatments, such as chemotherapy, as well as developing new drugs.”
The grant forms part of £2.3 million awarded to 20 projects around the UK and will fill one of the research gaps identified by the country’s top breast cancer experts in a recent study carried out by the charity.
Media Contacts: Vickie Woodward University of Wolverhampton Press Officer 01902